Lilly Announces Agreement To Acquire Loxo OncologyAcquisitions, B Cells, Biopharmaceutical, Business, Cancer, Oncology, Product Pipeline, TRK InhibitorsEli Lilly and Company and Loxo Oncology Inc. announced a definitive agreement for Lilly to acquire Loxo for $235.00 per share in cash, or approximately $8.0 billion. Read more January 7, 2019/by PR Newswire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 PR Newswire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png PR Newswire2019-01-07 06:30:502019-01-07 12:55:35Lilly Announces Agreement To Acquire Loxo Oncology
